

Essential (or primary) thrombocytopenia (ET) (short version)

Recommendations from the society for diagnosis and therapy of haematological and oncological diseases

Publisher

DGHO Deutsche Gesellschaft für Hämatologie und
Medizinische Onkologie e.V.

Bauhofstr. 12
D-10117 Berlin

Executive chairwoman: Prof. Dr. med. Claudia Baldus

Phone: +49 (0)30 27 87 60 89 - 0

info@dgho.de

www.dgho.de

Contact person

Prof. Dr. med. Bernhard Wörmann
Medical superintendent

Source

www.onkopedia-guidelines.info

The information of the DGHO Onkopedia Web Site is not intended or implied to be a substitute for professional medical advice or medical care. The advice of a medical professional should always be sought prior to commencing any form of medical treatment. To this end, all component information contained within the web site is done so for solely educational purposes. DGHO Deutsche Gesellschaft für Hämatologie und Onkologie and all of its staff, agents and members disclaim any and all warranties and representations with regards to the information contained on the DGHO Web Site. This includes any implied warranties and conditions that may be derived from the aforementioned web site information.

Table of contents

| | |
|---------------------------------------|----------|
| 1 Summary | 2 |
| 2 Therapy | 2 |
| 15 Authors' Affiliations | 3 |
| 16 Disclosures | 4 |

Essential (or primary) thrombocythemia (ET) (short version)

Date of document: August 2021

Compliance rules:

- [Guideline](#)
- [Conflict of interests](#)

Authors: Petro E. Petrides, Gabriela M. Baerlocher, Konstanze Döhner, Heinz Gisslinger, Martin Grieshammer, Steffen Koschmieder, Juliana Schwaab, Eva Lengfelder


1 Summary

Essential (or primary) thrombocythemia (ET or PT) is a chronic myeloproliferative neoplasia (MPN) (formerly chronic myeloproliferative disease, CMPE) characterized by a persistent increase in platelet count. On the basis of molecular biological analyses (mutations in the *JAK2*, *CALR*, *MPL genes*), different subtypes can be distinguished. Typical disease complications are thrombosis and bleeding. Inhibitors of platelet aggregation and cytoreductive drugs are available for primary and secondary prevention of these complications. In a proportion of ET cases, the disease progresses to polycythaemia vera (PV), post-ET myelofibrosis or myelodysplastic syndrome (MDS), or acute leukemia.

2 Therapy

The current treatment algorithm is depicted in [Figure 1](#).

Figure 1: Treatment algorithm in patients with essential thrombocythemia (ET), based on the conventional score



Legend:

■ curative treatment intent; ■ non-curative treatment intent;

¹Anagrelide is approved for the treatment of high-risk ET in the form of different preparations from different manufacturers, covering first- and second-line therapy in Germany, Austria and Switzerland.

²Pegylated interferon-alpha is only applicable as 'off label use'.

15 Authors' Affiliations

Prof. Dr. med. Gabriela M. Baerlocher

Universität Bern
 Labor für Hämatopoiese und Molekulare Genetik
 Murtenstrasse 40
 CH-3008 Bern
gabriela.baerlocher@hematology.ch

Prof. Dr. med. Konstanze Döhner

Universitätsklinikum Ulm
 Innere Medizin III
 Albert-Einstein-Allee 23
 89081 Ulm
konstanze.doehner@uniklinik-ulm.de

Prof. Dr. med. Heinz Gisslinger

Medizinische Universität in Wien
Universitätsklinik f. Innere Medizin I
Klinische Abteilung für Hämatologie und Hämostaseologie
Währinger Gürtel 18-20
A-1090 Wien
heinz.gisslinger@meduniwien.ac.at

Prof. Dr. med. Martin Griebhammer

Johannes Wesling Klinikum Minden
Klinik für Hämatologie / Onkologie
Hans-Nolte-Str. 1
32429 Minden
martin.griesshammer@muehlenkreiskliniken.de

Univ.-Prof. Dr. med. Steffen Koschmieder

Uniklinik RWTH Aachen
Med. Klinik IV
Hämatologie, Onkologie, Hämostaseologie & SZT
Pauwelsstr. 30
52074 Aachen
skoschmieder@ukaachen.de

Prof. Dr. med. Eva Lengfelder

Universitätsklinikum Mannheim
Medizinische Fakultät Mannheim d. Uni Heidelberg
III. Medizinische Klinik
Theodor-Kutzer-Ufer 1-3
68167 Mannheim
eva.lengfelder@medma.uni-heidelberg.de

Prof. Dr. med. Petro E. Petrides

Hämatologisch-Onkologische Schwerpunktpraxis
am Isartor
Zweibrückenstr. 2
80331 München
petrides@onkologiemuenchen.de

Prof. Dr. Juliana Schwaab

Universitätsmedizin Mannheim
III. Medizinische Klinik
Hämatologie und Internistische Onkologie
Theodor-Kulzer-Ufer 1-3
68167 Mannheim
juliana.schwaab@medma.uni-heidelberg.de

16 Disclosures

Conflicts of interest can be found in the full [German version of the guideline](#).